关键词
How to Cite
摘要
Частота отдельных злокачественных новообразований и сахарного диабета (СД), имеет тенденцию к росту. Это является одной из причин того, что СД все чаще привлекает к себе внимание как потенциальный фактор риска развития онкологических заболеваний. В то же время, в целом, сравнительно меньшее внимание уделяется анализу вопроса о том, способно ли наличие СД оказывать влияние на особенности новообразования, присущие ему при выявлении, а также на клиническое течение опухолевого процесса и его исходы. В настоящей публикации именно этот аспект проблемы рассмотрен на примере таких часто встречающихся и характеризующихся несомненной спецификой опухолей женской репродуктивной системы, как рак молочной железы и рак тела матки.参考
Баранов В.Л., Волкова Е.А.Ворохобина Н.В. и др. Эндокринология, том 2. - СПб.: СпецЛит, 2004. - 432 с.
Берштейн Л.М. Диабет, ожирение и онкологическая заболеваемость: риски и антириски // Сахарный диабет. - 2012. - № 4. - С. 81-88.
Берштейн Л.М. Онкоэндокринология: традиции, современность и перспективы. - СПб.: Наука, 2004. - 343 с.
Берштейн Л.М., Мерабишвили В.М., Карпова И.А. и др. Популяционный анализ сочетания рака и сахарного диабета: частота и особенности // Вопр. онкол. - 2007. - Т. 53. - С. 285-290.
Берштейн Л.М., Цырлина Е.В., Коваленко И.Г. и др. Рецепторный статус опухолей у курящих и страдающих сахарным диабетом больных раком молочной железы // Вопр. онкол. - 2005. - Т. 51. - С. 187-191.
Бохман Я.В. Руководство по онкогинекологии. - Л.: Медицина, 1989. - 464 с.
Дедов И.И., Шестакова М.В. Сахарный диабет (руководство для врачей). - М.: Медицинское информационное агентство, 2011. - 808 с.
Квачевская Ю.О. Особенности рака эндометрия при синдроме инсулинорезистентности: Автореф. дис. канд. мед. наук. - СПб, 2000. - 23 с.
Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов А.С. Опухоли молочной железы (лечение и профилактика). - Алмааты, 2001. - 344 с.
Солун М.Н., Куницына М.А. Сахарный диабет и злокачественные новообразования // Вопр.онкол. - 1987.-Т. 33 (11). - С.7-12.
Attias-Geva Z., Bentov I., Ludwig D.L. et al. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells // Eur J Cancer. - 2011. - Vol. 47 (11). - P 1717-1726.
Barone B.B., Yeh H.C., Snyder C.F. et al. Long-term allcause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis // JAMA. - 2008. -Vol. 300 (23). - P 2754-2764.
Berstein L.M., Boyarkina M.P., Tsyrlina E.V. et al. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin // Med Oncol. - 2011. - Vol. 28 (4). - P. 1260-1263.
Campbell P.T., Newton C.C., Patel A.V. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults // Diabetes Care. - 2012. - Vol. 35 (9). - P. 1835-1844.
Chen C, Smothers J, Lange A. et al. Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome // Minerva Endocrinol. - 2010. - Vol. 35 (4). - P 271-280.
Chen H.F., Liu M.D., Chen P. et al. Risks of Breast and Endometrial Cancer in Women with Diabetes: A Population-Based Cohort Study // PLoS one. - 2013. - Vol. 8 (6). - e67420.
Chen W.W., Shao Y.Y., Shau W.Y. The impact of diabetes mellitus on prognosis of early breast cancer in Asia // Oncologist. - 2012. - Vol. 17 (4). - P. 485-491.
Chia V.M., Newcomb А., Trentham-Dietz A., Hampton J.M. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis // Inter. J. Gyn. Cancer. - 2007. - Vol. 17 (2). - P. 441-446.
Cleveland R.J., North K.E., Stevens J. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project // Cancer Causes Control. - 2012. - Vol. 23 (7). -P 1193-1203.
Currie C.J., Poole C.D., Evans M. et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes // J Clin Endocrinol Metab. - 2013. - Vol. 98 (2). - P 668-677.
De Bruijn K.M., Arends L.R., Hansen B.E. et al. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer // Br. J. Surg. - 2013. - Vol. 100 (11). - P. 1421-1429.
Eliassen A.H., Hankinson S.E. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies // Adv Exp Med Biol. - 2008. - Vol. 630. - P. 148-165.
Ferguson R.D., Gallagher E.J., Cohen D. et al. Hyperin-sulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer // EndocrRelat Cancer. - 2013. - Vol. 20 (3). - Р. 391-401.
Ferguson R.D., Novosyadlyy R., LeRoith D. et al. Hyper-insulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes // Breast Cancer Res. - 2012. - Vol. 14 (1) - R 8.
Fleming S.T, Pursley H.G., Newman B. et al. Comorbidity as a predictor of stage of illness for patients with breast cancer // Med Care. - 2005. - Vol. 43. - P 132-140.
Folsom A.R., Anderson K.E., Sweeney C., Jacobs D.R. Diabetes as a risk factor for death following endometrial cancer // Gynecologic Oncology. - 2004. - Vol. 94 (3). - P. 740-745.
Gallagher E.J., LeRoith D. Minireview: IGF, Insulin, and Cancer // Endocrinology. - 2011. - Vol. 152 (7). - P. 2546-2551.
Giovannucci E., Harlan D.M., Archer M.C. et al. Diabetes and cancer: a consensus report // Diabetes Care. - 2010. - Vol. 33 (7). - P. 1674-1685.
Gliozzo B., Sung C.K., Scalia P. et al. Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway // J Cell Biochem. - 1998. - Vol. 70 (2). - P. 268-280.
Gr ndker C., G nthert A.R., Emons G. Hormonal heterogeneity of endometrial cancer // Adv Exp Med Biol. - 2008. - Vol. 630. - P 166-188.
Guastamacchia E., Resta F., Mangia A. et al. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets // Curr Drug Targets Immune EndocrMetabolDisord. - 2003. - Vol. 3 (3). - P 205-209.
Liao S., Li J., Wang L. et al. Type 2 diabetes mellitus and characteristics of breast cancer in China // Asian Pac J Cancer Prev. - 2010. - Vol. 11(4). - P933-937.
Mohanraj L, O h Y.Targeting. IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy // Recent Pat Anticancer Drug Discov. - 2011. - Vol. 6 (2). - P. 166-177.
Mountzios G., Pectasides D., Bournakis E. Developments in the systemic treatment of endometrial cancer // Crit Rev Oncol Hematol. - 2011. - Vol. 79 (3). - P. 278-292.
Nechuta S., Lu W., Zheng Y. et al. Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study // Breast Cancer Res Treat. - 2013. - Vol. 139 (1). - P. 227-235.
Papanas N., Giatromanolaki A., Galazios G. et al. Endometrial carcinoma and diabetes revisited // Eur J Gynaecol Oncol. - 2006. - Vol. 27 (5). -P. 505-508.
Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulinlike growth factors and neoplasia // Nat Rev Cancer. - 2004. - Vol. 4. - P. 505-518.
Rhomberg W. Metastasizing carcinoma of the breast and diabetes mellitus, a prognosticallyfavourable combination // Dtsch Med Wochenschr. - 1975. - Vol. 100 (47). - P. 2422-2427.
Richardson L.C., Pollack L.A. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer // Nat. Clin. Pract.Oncol. - 2005. -Vol. 2 (1). - P. 48-53.
Sanders J.L., Fitzpatrick A.L., Boudreau R.M. et al. Leukocyte telomere length is associated with noninvasively measured age-related disease: The Cardiovascular Health Study // J Gerontol A Biol Sci Med Sci. - 2012. - Vol. 67 (4). - P. 409-416.
Schnell O., Otter W., Standl E. The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, prediabetes, and cardiovascular disease into clinical practice // Diabetes Care. - 2009. - Vol. 32 - Suppl 2. - P 326-330.
Schveigert D., Cicenas S., Bruzas S. et al. The value of MMP-9 for breast and non-small cell lung cancer patients’ survival // Adv Med Sci. - 2013. - Vol. 58 (1). - P. 73-82.
Sciacca L., Vigneri R., Tumminia A. et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients // NutrMetabCardiovasc Dis. - 2013. - Vol. 23 (9). - P. 808-815.
Setiawan V.W., Yang H.P., Pike M.C. et al. Type I and II endometrial cancers: have they different risk factors? // J Clin Oncol. - 2013. - Vol. 31 (20). - P. 2607-2618.
Srokowski T.P., Fang S., Hortobagyi G.N. et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer // J ClinOncol. - 2009. - Vol. 27. - P. 2170-2176.
Steiner E., Eicher O., Hofmann M. et al. Endometrial carcinoma in patients with diabetes mellitus // ZentralblGyn-akol. - 2001. - Vol. 123 (11). - P 622-625.
Steiner E., Plata K., Interthal C. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients // Eur J GynaecolOncol. - 2007. - Vol. 28 (2). - P. 95-97.
Steiner E., Schmidt M., Weikel W., Koelbl H. Influence of diabetes mellitus and nodal distribution in endometrial cancer and correlation to clinico-pathological prognostic factors // Eur J GynaecolOncol. - 2006. - Vol. 27 (5). - P. 477-480.
Svenson U., Nordfj ll K., Stegmayr B. et al. Breast cancer survival is associated with telomere length in peripheral blood cells // Cancer Res. - 2008. - Vol. 68 (10). - P 3618-3623.
Van de Poll-Franse L.V., Houterman S., Janssen-Heijnen M.L. et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis // Int J Cancer. - 2007. - Vol. 120. - P. 1986-1992.
Vigneri P, Frasca F., Sciacca L. et al. Diabetes and cancer // Endocr. Relat.Cancer. - 2009. - Vol. 16 (4). - P 1103-1123.
Wang S., Li W., Liu N. et al. Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified // Med Oncol. - 2012. - Vol. 29 (4). - P. 2556-2564.
Xihong Z., Douglas Y. Tyrosine kinase signaling in breast cancer: Insulin-like growth factors and their receptors in breast cancer // Breast Cancer Res. - 2000. - Vol. 2 (3). - P 170-175.
Xu J., Chen Y. MYC and Breast Cancer // Genes Cancer. - 2010. - Vol. 1 (6). - P. 629-640.
Zanders M.M., Boll D., van Steenbergen L.N. et al. Effect of diabetes on endometrial cancer recurrence and survival // Maturitas. - 2013. - Vol. 74 (1). - P 37-43.
Zendehdel K., Nyrn O., Ostenson C.G.et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden // J Natl Cancer Inst. - 2003. - Vol. 95 (23). - P. 1797-1800.
Zhang J., Lu A., Beech D., Jiang B., Lu Y. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis // Cancer Ther. - 2007. -Vol. 5. - P. 273-286.
Zhang Z.H., Su P.Y., Hao J.H., Sun Y.H. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies // Int J Gynecol Cancer. - 2013. - Vol. 23 (2). - P. 294-303.
Zhu C., Qi X., Chen Y. et al. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer // J Cancer Res Clin Oncol. - 2011. - Vol. 137 (11). - P 1587-1594.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2014